uniQure to Announce Third Quarter Financial Results
uniQure N.V. (NASDAQ: QURE), a pioneering company in gene therapy, is gearing up to announce its financial results for the third quarter of the year. The announcement will be made before the market opens, providing investors and analysts a comprehensive look into the company's financial health and advances in the field.
Conference Call Details
On the day of the earnings release, management will host a conference call at 8:30 a.m. ET. This call will allow participants to engage directly with the management team, presenting an opportunity for insightful discussions around the results and the strategic direction of uniQure.
How to Join the Call
Analysts and interested parties wishing to participate in the live Q&A session can dial (646) 307-1963 or toll-free (800) 715-9871 and enter the passcode 2196195. It is advised to join the call approximately 15 minutes prior to the scheduled start.
Webcast Information
For those interested in following the event online, the conference will be available for live streaming through the Events & Presentations section of uniQure's website. Following the event, a replay will be accessible for 90 days, ensuring that those who cannot attend live can catch up at their convenience.
About uniQure's Innovations
uniQure has been at the forefront of developing gene therapies that offer potentially curative treatments through single administration. Their landmark achievement with gene therapy for hemophilia B marks a significant milestone in genomic medicine—opening new avenues for treating complicated conditions.
Advancing Gene Therapy Pipeline
The company is not resting on its laurels; it continues to expand its pipeline with the development of innovative gene therapies targeting various severe diseases, including Huntington's disease, refractory temporal lobe epilepsy, Amyotrophic Lateral Sclerosis (ALS), and Fabry disease. Each of these efforts underlines uniQure's commitment to delivering meaningful therapeutic options to patients in need.
Contact Information for Investors and Media
uniQure provides dedicated contacts for investor and media inquiries. For investor relations, Chiara Russo is available at 781-491-4371 or via mobile at 617-306-9137. She can be reached through email at c.russo@uniQure.com.
For media inquiries, Tom Malone is your go-to contact at 339-970-7558 or mobile 339-223-8541. He can be contacted via email at t.malone@uniQure.com.
Frequently Asked Questions
When is uniQure releasing its Q3 2025 financial results?
uniQure will announce its third quarter financial results before the market opens on November 10, 2025.
How can I participate in the earnings call?
To join the call, dial (646) 307-1963 or (800) 715-9871 and enter the passcode 2196195, preferably 15 minutes early.
Where can I find the webcast of the earnings call?
The event will be streamed live on the Events & Presentations section of uniQure's website, and a replay will be available for 90 days thereafter.
What new therapies is uniQure working on?
uniQure is advancing therapies for conditions including Huntington's disease, ALS, and Fabry disease, among others.
Who can I contact for more information?
For inquiries related to investors, you can contact Chiara Russo. For media-related questions, reach out to Tom Malone.
